Diagnostics clinique, urétéroscopique et photodynamique des tumeurs de la voie excrétrice urinaire supérieures : état-de-l’art pour le rapport scientifique annuel de l’Association française d’urologie

Nison, L.; Bozzini, Giorgio; Rouprêt, Morgan; Traxer, Olivier; Colin, P.

doi:10.1016/j.purol.2014.07.012

Cited by 18 publications

(2 citation statements)

References 48 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Flexible ureterorenoscopy allows for the exploration of the entire upper urinary tract, as well as for direct visualisation and biopsy of the lesion. The sensitivity of biopsy in the diagnosis of UC is 89-95% [34]. Its reliability in predicting the tumour stage is low, with a high rate of underestimation (45% of Ta lesions are actually infiltrating tumours) [34].…”

Section: Diagnosismentioning

confidence: 99%

“…The sensitivity of biopsy in the diagnosis of UC is 89-95% [34]. Its reliability in predicting the tumour stage is low, with a high rate of underestimation (45% of Ta lesions are actually infiltrating tumours) [34]. Also, there is a rising concern that ureterorenoscopy increases the risk of intravesical recurrence [35], and a risk-stratified approach has been proposed to avoid this in high-risk cases [36].…”

Section: Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Clinical and Biological Differences between Upper Tract Carcinoma and Bladder Urothelial Cancer, Including Implications for Clinical Practice

Lefort,

Rhanine,

Larroquette

et al. 2023

Cancers

View full text Add to dashboard Cite

Upper tract urothelial carcinoma (UTUC) is a rare disease included, along with the much more frequent urothelial bladder cancer (BUC), in the family of urothelial carcinomas (UCs). However, while UTUCs and BUCs share several features, their epidemiological, clinical, pathological, and biological differences must be considered to establish an optimal therapeutic strategy. This review examines the clinical differences between UTUC and BUC, as well as the main results obtained by molecular screening of the two diseases. The findings of clinical trials, performed in peri-operative and metastatic settings and assessing systemic treatments in UC, are summarised. A comparison of the data obtained for UTUC and BUC suggests improved therapeutic approaches, both in regards to routine practice and future drug development.

show abstract

Section: Diagnosismentioning

confidence: 99%